We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Ezetimibe (Zetia)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Ezetimibe (Zetia) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2003–2018 with a typical study size of 9,438 participants.
Based on 7 studies · 4 RCTs · 29,455 total participants
Confidence
ModerateBy outcome
Ezetimibe (Zetia) has an evidence score of 4.4/10 — strong evidence based on 7 indexed studies, including 1 meta-analysis. A prescription oral cholesterol-absorption inhibitor (Zetia) that blocks the intestinal NPC1L1 sterol transporter, lowering LDL-C ~15–20% on its own and more when added to a statin. In IMPROVE-IT (~18,000 post-ACS patients) ezetimibe added to simvastatin cut cardiovascular events — the first proof a non-statin LDL-lowering drug improves outcomes. Very well tolerated; rare myalgia and small liver-enzyme rise. Prescription drug, not a supplement. Representative study: PMID 30480766.
The commonly studied dose of Ezetimibe (Zetia) is 10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Notable regimens that report including Ezetimibe (Zetia) — documented, not endorsed.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Ezetimibe (Zetia) — cholesterol-absorption inhibitor
A prescription oral cholesterol-absorption inhibitor (Zetia) that blocks the intestinal NPC1L1 sterol transporter, lowering LDL-C ~15–20% on its own and more when added to a statin. In IMPROVE-IT (~18,000 post-ACS patients) ezetimibe added to simvastatin cut cardiovascular events — the first proof a non-statin LDL-lowering drug improves outcomes. Very well tolerated; rare myalgia and small liver-enzyme rise. Prescription drug, not a supplement.
Ezetimibe has strong human evidence: a clear NPC1L1 mechanism, consistent LDL-lowering across RCTs, and the IMPROVE-IT outcome trial showing added cardiovascular benefit when combined with a statin — the first such proof for a non-statin. The score is tempered by a modest monotherapy effect and its strongest outcome data being as a statin add-on rather than stand-alone.
Ezetimibe is an oral cholesterol-absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter on the brush border of intestinal enterocytes, reducing the absorption of dietary and biliary cholesterol.
This lowers cholesterol delivery to the liver, up-regulates hepatic LDL receptors, and clears LDL-C from the blood — a mechanism complementary to and distinct from statins (which block cholesterol synthesis).
As monotherapy ezetimibe lowers LDL-C roughly 15–20%; added on top of a statin it provides a further ~20% reduction, which is why it is most often combined (Vytorin = ezetimibe + simvastatin; Nexlizet = ezetimibe + bempedoic acid).
The landmark outcome trial, IMPROVE-IT (NEJM 2015, ~18,000 patients after acute coronary syndromes), showed that ezetimibe added to simvastatin significantly reduced major cardiovascular events versus simvastatin alone — the first demonstration that a non-statin LDL-lowering drug improves clinical outcomes, reinforcing the 'lower LDL is better' principle.
Supporting trials include SHARP (ezetimibe + simvastatin in chronic kidney disease) and SEAS (in aortic stenosis), and a Cochrane review confirms modest event reductions.
The honest distinction: as monotherapy the LDL effect is real but modest, and its strongest outcome evidence is as an add-on to a statin rather than as a stand-alone therapy. Ezetimibe is very well tolerated — generally comparable to placebo — with only rare myalgia and small, usually transient liver-enzyme elevations.
It is a prescription drug and is presented here for informational purposes only, not as a recommendation; the score reflects genuinely strong human LDL and cardiovascular-outcome evidence against a modest monotherapy effect.
Blocks the intestinal Niemann-Pick C1-Like 1 sterol transporter, reducing absorption of dietary and biliary cholesterol from the gut.
Less cholesterol reaches the liver, so hepatic LDL receptors increase and clear more LDL-C from the blood.
Inhibits absorption rather than synthesis, so combining with a statin (which blocks synthesis) produces additive LDL lowering.
How Ezetimibe (Zetia) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.
Loading: No loading dose; the standard dose is 10 mg once daily.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (ezetimibe 10 mg) | Recommended |
| 💊Vytorin (ezetimibe + simvastatin) | Alternative |
| 💊Nexlizet (ezetimibe + bempedoic acid) | Alternative |
Often prescribed as a fixed-dose combination when additional LDL lowering beyond a statin is needed, or as monotherapy in statin-intolerant patients.
Minimum: 4 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once daily at any time; if combined with a bile-acid sequestrant, take ezetimibe at least 2 hours before or 4 hours after it.
Dose-response data unavailable. The current published research for Ezetimibe (Zetia) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lowers LDL-C ~15–20% as monotherapy and ~20% further when added to a statin.
Added to simvastatin, reduced major cardiovascular events in post-ACS patients (IMPROVE-IT).
Adverse-event profile is close to placebo in trials, making it useful for statin-intolerant patients.
Alone, the LDL drop is smaller than a moderate-intensity statin; outcome benefit is clearest as a statin add-on.
Occasional muscle aches and small, usually transient transaminase elevations; very rare rhabdomyolysis, mostly when combined with a statin.
Often a good fit as monotherapy or with a low statin dose — tolerability is close to placebo.
Not recommended — exposure is increased and data are limited.
Avoid, particularly in combination with a statin.
Reduce ezetimibe absorption; separate dosing by several hours.
Additive LDL lowering (intended); very rare additive myopathy/liver-enzyme risk.
Raises ezetimibe (and cyclosporine) blood levels; monitor closely.
Tip: Usually mild; more likely when combined with a statin. Report persistent or severe muscle pain.
Tip: Small, usually transient transaminase rise, mainly in statin combinations; periodic liver-function monitoring.
Tip: Generally self-limiting; take with food if it helps.
Tip: Very rare, mainly with concomitant statins; seek care for severe muscle pain with dark urine.
Timing is flexible for Ezetimibe (Zetia) — consistent daily use matters more than the time of day. Can be taken at any time of day with or without food; separate from bile-acid sequestrants, which bind it.
Ezetimibe (Zetia) is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are myalgia (muscle aches), elevated liver enzymes, diarrhea / abdominal discomfort. Use caution if any of these apply to you: Active liver disease or unexplained persistent transaminase elevations (when combined with a statin); Pregnancy and breastfeeding (especially in combination with a statin); Known hypersensitivity to ezetimibe.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.
May increase cholesterol in bile and gallstone risk; gemfibrozil raises ezetimibe levels.